Single CAR T Injection Shows Promise for Multiple Sclerosis Symptoms in Early Trial

In vivo CAR T cell therapy reduced MS symptoms and autoantibodies in 16 patients without complex lab production

A trial with 16 patients suffering from multiple sclerosis and other neurological autoimmune disorders demonstrated symptom improvement after a single intravenous injection of a viral vector designed to reprogram the body’s own T cells. All participants maintained stable safety profiles over six months, with documented reductions in fatigue, enhanced motor and cognitive function, and lower nerve injury markers. Disease-causing B cell levels dropped significantly within 1-2 months, and newly generated B cells showed absence of autoantibody production in the group. The therapy avoids traditional lab-based cell production, potentially simplifying manufacturing and reducing costs for millions of people living with MS.

This approach—delivering genetic instructions directly to reprogram endogenous T cells in vivo—could make MS treatment more accessible if it scales beyond the trial’s small size. By eliminating the need for complex, personalized cell production, it may lower barriers to affordability for conditions currently requiring expensive, specialized therapies.

Key caveats include the absence of a control group and the trial’s limited scope. Long-term safety remains uncertain due to potential viral DNA integration, and effects observed here may not extend to broader autoimmune conditions. The next step is confirming whether these benefits hold in larger, controlled studies.

Source: Singularity Hub